当前位置: 首页 > 期刊 > 《世界华人消化杂志》 > 2006年第13期
编号:11123804
低剂量乙肝免疫球蛋白与拉米夫定长期联用预防肝移植后HBV复发
http://www.100md.com 夏念信, 傅志仁, 邱宝安, 王正昕, 李先兴,
肝移植;乙型肝炎病毒;人乙肝免疫球蛋白;拉米夫定;阿德福韦;复发,夏念信,邱宝安,白刚,杨英祥,王昆,傅志仁,王正昕,李先兴,夏念信,通讯
第2页
第1页

    参见附件(912KB,6页)。

     夏念信, 邱宝安, 白刚, 杨英祥, 王昆, 海军总医院肝胆外科 北京市 100037

    傅志仁, 王正昕, 李先兴, 第二军医大学长征医院全军器官移植研究所 上海市 200003

    夏念信, 2005年第二军医大学医学硕士毕业, 主要从事肝胆胰疾病的临床治疗和研究工作.

    国家自然科学基金资助项目, No. 30471643

    通讯作者: 夏念信, 100037, 北京阜成路6号, 海军总医院肝胆外科. xnxdoctor@yahoo.com.cn

    收稿日期: 2006-02-24 接受日期: 2006-03-20

    Low-dose intra-muscular hepatitis B immunoglobulin combined with lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation

    Nian-Xin Xia, Zhi-Ren Fu, Bao-An Qiu, Zheng-Xin Wang, Xian-Xing Li, Gang Bai, Ying-Xiang Yang, Kun Wang

    Nian-Xin Xia, Bao-An Qiu, Gang Bai, Ying-Xiang Yang, Kun Wang, Department of Hepatobiliary Surgery, Navy General Hospital of Chinese PLA, Beijing 100037, China

    Zhi-Ren Fu, Zheng-Xin Wang, Xian-Xing Li, Institute of Organ Transplantation, Changzheng Hospital of the Second Military Medical University, Shanghai 200003, China

    Supported by the National Natural Science Foundation of China, No. 30471643

    Correspondence to: Nian-Xin Xia, Department of Hepatobiliary Surgery, Navy General Hospital of Chinese PLA, Beijing 100037, China. xnxdoctor@yahoo.com.cn

    Received: 2006-02-24 Accepted: 2006-03-20

    Abstract

    AIM: To evaluate the efficacy of long-term, low-dose intra-muscular hepatitis B immunoglobulin (HBIg) combined with lamivudine (LAM) in patients who received orthotopic liver transpl-ants (OLT) and have been followed up for acute or chronic HBV-related end-stage liver disease.

    METHODS: The liver transplantation recipients (n = 173) who have been followed up and received antiviral prophylaxis post-OLT were divided into 3 sub-groups according to their post-OLT antiviral therapy, which were group A (LAM monotherapy, n = 2), group B (HBIg and LAM therapy, n = 168) and group C (HBIg and ADF therapy n = 3). All the patients received LAM treatment for 1 or 2 wk ahead of OLT. Either LAM (100 mg) or ADF (adefovir dipivoxil, 10 mg) was administered orally every day ......

您现在查看是摘要介绍页,详见PDF附件(912KB,6页)